News About: Pharm. Industry
Pharmacy-oriented cosmetics market contested by three firms
Pharmaceutical business sources say that a major change in the domestic pharmacy-oriented cosmetics market is in the marking inasmuch as Yuhan Corp. is pushing ahead with aggressive marketing offensive and thus, this ...
Patent dispute over EPO is still underway
In the recent patent dispute filed by Genetics Institute (GI) that Cheil Jedang's Epokine (erithropoietin), which was developed by the latter's own technology for the third time in the world, had infringed the former'...
Concerns arise over new drug pricing system
Amid the domestic pharmaceutical industry's concerns over the repeated cuts in insurance drug prices following the government's more strict ex post facto drug management, the new reimbursement prices re-evaluation sys...
Bioventure firms struggling to explore overseas markets
The domestic bioventure firms, which have recently experienced serious setbacks, are endeavoring to explore overseas markets with concerted efforts of their normalized business operations.
They have selected more l...
Various themes presented in scientific symposium of Osong International Bio Exposition
During the recent two-day scientific symposium with a theme of "New Therapeutic Approaches in the 21st Century", a variety of interesting subjects were presented by renowned scientists from all over the world. Excerpt...
Hawon Pharm. Co. appointed as good potential company.
Hawon pharmaceutical company has been assessed by the KIST with high standardized enterprise in terms of their product and R&D capability and recently received a letter of merit from the KIST.
For the purpose of su...
Overseas business association in pharmaceutical and bio-tech industry on the rise.
The overseas business exchange in the pharmaceutical and bio-tech business industry has shown a substantial increase accelerated by the KPMA, the Korea Health Industry Development Institute (KHIDI), the Korea Pharmac...
Foreign drug corporations unsatisfied with recent public criticisms.
Recently the Korean people, government and press have opined the foreign drug corporations as an unethical enterprise in Korea mainly as the NHI financial difficulties become key issues in connection with their almost...
Leading pharmaceutical firms recognizing importance of reimbursement prices management
Amid the government's subsequent drug-related policies aiming at reducing the reimbursement prices for better finance stability of the National Health Insurance Corp., the significance over the profit management throu...
M&A between Sanofi-Synthelabo and Keunwha went failure.
The business M&A between Sanofi-Synthelabo and Keunwha has gone failure according to their official announcement on Sept. 30.
Earlier on Sept. 3 the National Tax Service interpreted that the agreement for the trans...
